Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis

Lymphoma, Large B-Cell, Diffuse Clinical Trial

— Bio-CHIC  

Official title:

Biomarker Driven and Dose Intensified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk Diffuse Large B-Cell Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03293173
• Other study ID #: NLG-LBC-06
• Status: Recruiting
• Phase: Phase 2
• Start date: August 4, 2017
• Est. completion date: June 2024

Study information

• Verified date: March 2020
• Source: Nordic Lymphoma Group
• Contact: Laura K Hakala
• Phone: +358503729043
• Email: ext-laura.k.hakala[@]hus.fi
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is testing whether stratification of the patients according to biological risk factors for different treatment groups will improve the outcome of patients with clinically high diffuse large B-cell lymphoma (DLBCL).

Description:

For young clinically high-risk diffuse large B-cell lymphoma (DLBCL) patients the optimal therapy has not been established. Previous Nordic phase II studies, where dose-dense chemoimmunotherapy (R-CHOEP-14) with systemic CNS prophylaxis (HD-Mtx and HD-AraC) was given, demonstrated favorable outcome in comparison to historical controls. However, the patients with biological risk factors, such as translocation of bcl2 and myc oncogenes or and/or high BCL2 and MYC expression or deletion 17p and/or high P53 expression had significantly higher risk of death, as compared to patients without aberrations. The figures provide evidence for an unmet clinical need for the patients with biological risk factors, and underscore the importance of a clinical trial, where both biological and clinical risk factors play a role in the treatment planning.

In this trial treatment intensity varies according to presence or absence of biological risk factors. All patients receive a prephase medication consisting of prednisone and vincristine and two cycles of R-CHOP and high dose (HD) methotrexate. Subsequently, depending on the biological risk factors either four additional cycles of R-CHOEP (standard arm with no risk factors) or four dose adjusted R-EPOCH courses (experimental arm with risk factors) are given, followed by one course of high dose cytarabine (Ara-C) and R. R-CHOEP courses should be given with a two-week and R-EPOCH with a three-week interval.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: June 2024
• Est. primary completion date: December 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Age 18 - 64 years

• Histologically confirmed CD20+ DLBCL based on revised WHO 2008 Lymphoma Classification. The following subgroups and variants can be included:

• ALK-positive large B-cell lymphoma

• Intravascular large B-cell lymphoma

• T-cell rich B-cell lymphoma

• Myc/BCL-2 double hit lymphoma

• Follicular lymphomas grade 3b

• DLBCL with previously undiagnosed concurrent small cell infiltration in bone marrow, lymph node, or extranodal site and lymphomas intermediate between DLBCL and Burkitt's lymphoma are allowed

• Posttransplantation lymphoma (PTLD), discordant or transformed lymphoma are NOT allowed

• Patients in at least stage II with age adjusted IPI score of 2 or 3:

• Stage III /IV and elevated LDH

• Stage III/IV and WHO performance status 2 - 3

• Stage II and elevated LDH and WHO performance status 2 - 3

• And/or patients with site specific risk factors for CNS recurrence defined as follows

• More than one extranodal site

• Testicular lymphoma, stage IIE and higher

• Paranasal sinus and orbital lymphoma with destruction of bone

• Large cell lymphoma infiltration of the bone marrow

• Previously untreated, except steroids allowed

• WHO performance status 0-3

• Written informed consent

Exclusion Criteria:

• Severe cardiac disease: cardiac function grade 3-4, left ventricular ejection fraction <45%

• Impaired bone marrow liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule (Hemoglobin < 9 g/dL, ANC < 1.5 × 109/L, Platelet count < 75 × 109/L, creatinine clearance < 40 mL/min, ALT/AST > 2.5 x ULN, bilirubin 1.5 x ULN, INR > 1.5)

• Pregnancy/lactation

• Men and women of reproductive potential not agreeing to use effective contraception during treatment and for 18 months after completion of treatment (Effective contraception is combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device (IUD), hormone-releasing IUD, bilateral tubal occlusion, vasectomised partner, or sexual abstinence

• Patients with other severe medical problems, including active infections, cardiac or pulmonary disease, history of PML and with an expected short survival for non-lymphoma reasons

• Known HIV positivity

• Active or chronic hepatitis B virus (HBV) infection (defined as positive HBsAg serology), or active hepatitis C virus (HCV) infection (defined by antibody serology testing). HBsAg, HBcAb, and HCVAb must be tested during screening. Patients who have protective titers of HBsAb along negative HBsAg after vaccination or prior but cured hepatitis B are eligible.

• Vaccination with a live vaccine within one month prior to randomization

• Patients with a malignancy that has been treated but not with curative intent, unless the malignancy has been in remission without treatment for = 5 years prior to enrollment

• Earlier treatment containing anthracyclines

• Psychiatric or mental disorder which make the patient unable to give an informed consent and/or adhere to the protocol

• CNS disease as diagnosed by MRI or CSF cytology. Positive CSF flow cytometry below diagnostic threshold level by cytology is allowed

• Transformed lymphoma

• Primary mediastinal B-cell lymphoma

• Pleural or peritoneal fluid that cannot be drained safely

• Hypersensitivity to the active substance or any of the other ingredients

• History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products

• Patients participating in other clinical studies, unless followed for survival

• Lower urinary tract constriction, which cannot be treated adequately

• Degenerative and toxic encephalopathy

• Neuromuscular disease

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Large B-Cell, Diffuse

Intervention

Combination Product:
• R-CHOEP
rituximab, cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone
• DA-EPOCH-R
dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab

Locations

Country	Name	City	State
Denmark	Aarhus University Hospital	Aarhus
Denmark	Dept of Haematology, Rigshospitalet	Copenhagen
Denmark	Dept of Haematology, Herlev Hospital, Copenhagen	Herlev
Denmark	Dept haematology, Odense University hospital	Odense
Denmark	Dept of Haematology, Sjaellands University hospital, Roskilde	Roskilde
Finland	Helsinki University Hospital Cancer Centre	Helsinki
Finland	Keski-Suomen keskussairaala	Jyväskylä
Finland	Kuopio University Hospital	Kuopio
Finland	TAYS	Tampere
Finland	Turku University Hospital, Syöpäklinikka	Turku
Norway	Dept. of Oncology, Helse Bergen HF Haukeland sykehus	Bergen
Norway	Oslo University Hospital	Oslo
Norway	Dept. of Haematology and Oncology, Helse Stavander HF sykehuset	Stavanger
Norway	Dept. of Oncology, Universitetssykehuset i Nord-Norge HF	Tromsø
Norway	Dept of Oncology, St. Olavs hospital HF	Trondheim
Sweden	Skåne University Hospital	Lund

Sponsors (3)

Lead Sponsor	Collaborator
Nordic Lymphoma Group	Aarhus University Hospital, Helsinki University Central Hospital

Countries where clinical trial is conducted

Denmark,  Finland,  Norway,  Sweden, 

References & Publications (2)

Fiskvik I, Beiske K, Delabie J, Yri O, Spetalen S, Karjalainen-Lindsberg ML, Leppä S, Liestøl K, Smeland EB, Holte H. Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma. Leuk Lymphoma. 2015 Jun;56(6):1742-9. doi: 10.3109/10428194.2014.970550. Epub 2014 Nov 19. — View Citation

Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2013 May;24(5):1385-92. doi: 10.1093/annonc/mds621. Epub 2012 Dec 17. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to treatment failure (TTF) of the patients with biological risk factors	Interval between the registration date and the date of documented progression or lack of response, first relapse, death for any reason or discontinuation/change of therapy because of toxicity, whichever occurs first. Otherwise, patients will be censored at the last date they were known to be alive. For patients not responding at any time point on study treatment, TTF is defined as one day.	At 3 years
Secondary	Time to treatment failure (TTF) at 3 years from date of registration of all patients and the patients in the low risk group	Interval between the registration date and the date of documented progression or lack of response, first relapse, death for any reason or discontinuation/change of therapy because of toxicity, whichever occurs first. Otherwise, patients will be censored at the last date they were known to be alive. For patients not responding at any time point on study treatment, TTF is defined as one day.	At 3 years
Secondary	Incidence of treatment-emergent adverse events (Safety and tolerability)	Number of patients with treatment-related adverse events graded according to the NCI CTCAE v 4.03	During the treatment period at the end of each cycle (14 or 21 days) up to 6 months. In addition, severe late toxicities during follow-up at 6 months intervals through study completion, an average of 5.5 years.
Secondary	Clinical response rate of all patients and the patients with biological risk factors	Number of patients with complete or partial response	At the end of treatment cycles 2 and 7. Each cycle is two (group A) or three weeks (group B)
Secondary	CNS relapse rate	Number of patients with CNS progression	At 1,5 years
Secondary	Progression free survival rate (PFS) of all patients and the patients with biological risk factors		At 3 years
Secondary	Overall survival rate (OS) of all patients and the patients with biological risk factors		At 3 years
Secondary	Molecular correlates for survival	Identification of genomic aberrations (for example mutations and translocations), gene expression profiles and protein expression from the tumor tissue and circulation that predict clinical course of the disease	At 3 years